Across TCGA pan-cancer cohorts, BTBD17 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of BTBD17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where BTBD17 RNA is repressed in tumor relative to normal tissue. In most cancer types BTBD17 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, BRCA, and LIHC are the cancer types where BTBD17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTBD17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−0.929	<.001	10	view →
BRCA	All	III,IV	−0.081	<.001	6	view →
LIHC	All	All	+0.025	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: BTBD17 RNA expression & survival · all BTBD17 data types